nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—Mepyramine—Rosiglitazone—type 2 diabetes mellitus	0.202	1	CrCrCtD
Methotrimeprazine—ADRA2A—type 2 diabetes mellitus	0.093	0.299	CbGaD
Methotrimeprazine—HTR2C—type 2 diabetes mellitus	0.0856	0.275	CbGaD
Methotrimeprazine—CYP2E1—type 2 diabetes mellitus	0.0679	0.218	CbGaD
Methotrimeprazine—CYP1A2—type 2 diabetes mellitus	0.0646	0.208	CbGaD
Methotrimeprazine—DRD5—Bromocriptine—type 2 diabetes mellitus	0.0449	0.133	CbGbCtD
Methotrimeprazine—DRD4—Bromocriptine—type 2 diabetes mellitus	0.032	0.0949	CbGbCtD
Methotrimeprazine—ADRA1D—Bromocriptine—type 2 diabetes mellitus	0.0253	0.0749	CbGbCtD
Methotrimeprazine—DRD3—Bromocriptine—type 2 diabetes mellitus	0.0238	0.0706	CbGbCtD
Methotrimeprazine—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.0229	0.068	CbGbCtD
Methotrimeprazine—DRD1—Bromocriptine—type 2 diabetes mellitus	0.0229	0.068	CbGbCtD
Methotrimeprazine—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.0218	0.0645	CbGbCtD
Methotrimeprazine—ADRA1B—Bromocriptine—type 2 diabetes mellitus	0.0184	0.0545	CbGbCtD
Methotrimeprazine—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.0168	0.0497	CbGbCtD
Methotrimeprazine—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0151	0.0448	CbGbCtD
Methotrimeprazine—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.0151	0.0448	CbGbCtD
Methotrimeprazine—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0145	0.043	CbGbCtD
Methotrimeprazine—DRD2—Bromocriptine—type 2 diabetes mellitus	0.0139	0.0413	CbGbCtD
Methotrimeprazine—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.0082	0.0243	CbGbCtD
Methotrimeprazine—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00732	0.0217	CbGbCtD
Methotrimeprazine—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00676	0.02	CbGbCtD
Methotrimeprazine—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00646	0.0191	CbGbCtD
Methotrimeprazine—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00611	0.0181	CbGbCtD
Methotrimeprazine—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00555	0.0165	CbGbCtD
Methotrimeprazine—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00532	0.0158	CbGbCtD
Methotrimeprazine—CYP1A2—Losartan—type 2 diabetes mellitus	0.00416	0.0123	CbGbCtD
Methotrimeprazine—Liver injury—Acarbose—type 2 diabetes mellitus	0.0019	0.0348	CcSEcCtD
Methotrimeprazine—Drug interaction—Chlorpropamide—type 2 diabetes mellitus	0.00179	0.0328	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Acarbose—type 2 diabetes mellitus	0.0016	0.0293	CcSEcCtD
Methotrimeprazine—HTR2A—arteriole—type 2 diabetes mellitus	0.00137	0.121	CbGeAlD
Methotrimeprazine—Liver injury—Glipizide—type 2 diabetes mellitus	0.00131	0.024	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Glipizide—type 2 diabetes mellitus	0.0011	0.0202	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Tolbutamide—type 2 diabetes mellitus	0.00105	0.0192	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Tolbutamide—type 2 diabetes mellitus	0.000955	0.0175	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Tolazamide—type 2 diabetes mellitus	0.000954	0.0174	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Chlorpropamide—type 2 diabetes mellitus	0.000954	0.0174	CcSEcCtD
Methotrimeprazine—Weight increased—Linagliptin—type 2 diabetes mellitus	0.000941	0.0172	CcSEcCtD
Methotrimeprazine—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.000875	0.0771	CbGeAlD
Methotrimeprazine—Jaundice—Acarbose—type 2 diabetes mellitus	0.000872	0.016	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Tolazamide—type 2 diabetes mellitus	0.000869	0.0159	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Chlorpropamide—type 2 diabetes mellitus	0.000869	0.0159	CcSEcCtD
Methotrimeprazine—DRD1—nerve—type 2 diabetes mellitus	0.000849	0.0748	CbGeAlD
Methotrimeprazine—Jaundice—Nateglinide—type 2 diabetes mellitus	0.000841	0.0154	CcSEcCtD
Methotrimeprazine—Drug interaction—Valsartan—type 2 diabetes mellitus	0.000756	0.0138	CcSEcCtD
Methotrimeprazine—Drug interaction—Orlistat—type 2 diabetes mellitus	0.000747	0.0137	CcSEcCtD
Methotrimeprazine—Jaundice—Repaglinide—type 2 diabetes mellitus	0.000728	0.0133	CcSEcCtD
Methotrimeprazine—Weight increased—Rosiglitazone—type 2 diabetes mellitus	0.00072	0.0132	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Sitagliptin—type 2 diabetes mellitus	0.000681	0.0125	CcSEcCtD
Methotrimeprazine—Drug interaction—Irbesartan—type 2 diabetes mellitus	0.00065	0.0119	CcSEcCtD
Methotrimeprazine—Urinary retention—Bromocriptine—type 2 diabetes mellitus	0.000642	0.0117	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Glipizide—type 2 diabetes mellitus	0.000633	0.0116	CcSEcCtD
Methotrimeprazine—Photosensitivity—Gliclazide—type 2 diabetes mellitus	0.000631	0.0115	CcSEcCtD
Methotrimeprazine—Constipation—Miglitol—type 2 diabetes mellitus	0.000621	0.0114	CcSEcCtD
Methotrimeprazine—Drowsiness—Glipizide—type 2 diabetes mellitus	0.000618	0.0113	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Bromocriptine—type 2 diabetes mellitus	0.000617	0.0113	CcSEcCtD
Methotrimeprazine—Weight increased—Pioglitazone—type 2 diabetes mellitus	0.000604	0.011	CcSEcCtD
Methotrimeprazine—Jaundice—Glipizide—type 2 diabetes mellitus	0.000602	0.011	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Glimepiride—type 2 diabetes mellitus	0.00059	0.0108	CcSEcCtD
Methotrimeprazine—Weight increased—Glimepiride—type 2 diabetes mellitus	0.000589	0.0108	CcSEcCtD
Methotrimeprazine—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.000588	0.0518	CbGeAlD
Methotrimeprazine—Weight increased—Sitagliptin—type 2 diabetes mellitus	0.000587	0.0107	CcSEcCtD
Methotrimeprazine—Photosensitivity—Valsartan—type 2 diabetes mellitus	0.00058	0.0106	CcSEcCtD
Methotrimeprazine—Liver injury—Ramipril—type 2 diabetes mellitus	0.000578	0.0106	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Glipizide—type 2 diabetes mellitus	0.000577	0.0105	CcSEcCtD
Methotrimeprazine—Drowsiness—Glimepiride—type 2 diabetes mellitus	0.000577	0.0105	CcSEcCtD
Methotrimeprazine—Jaundice—Glimepiride—type 2 diabetes mellitus	0.000562	0.0103	CcSEcCtD
Methotrimeprazine—HTR2A—hindlimb—type 2 diabetes mellitus	0.000544	0.048	CbGeAlD
Methotrimeprazine—Agranulocytosis—Glimepiride—type 2 diabetes mellitus	0.000538	0.00984	CcSEcCtD
Methotrimeprazine—Drug interaction—Ramipril—type 2 diabetes mellitus	0.000524	0.00959	CcSEcCtD
Methotrimeprazine—Drowsiness—Bromocriptine—type 2 diabetes mellitus	0.00052	0.00951	CcSEcCtD
Methotrimeprazine—Constipation—Linagliptin—type 2 diabetes mellitus	0.000503	0.00919	CcSEcCtD
Methotrimeprazine—DRD2—nerve—type 2 diabetes mellitus	0.000502	0.0442	CbGeAlD
Methotrimeprazine—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.000499	0.044	CbGeAlD
Methotrimeprazine—Photosensitivity—Irbesartan—type 2 diabetes mellitus	0.000498	0.00911	CcSEcCtD
Methotrimeprazine—Constipation—Acarbose—type 2 diabetes mellitus	0.000488	0.00893	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Glyburide—type 2 diabetes mellitus	0.000487	0.0089	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Ramipril—type 2 diabetes mellitus	0.000486	0.0089	CcSEcCtD
Methotrimeprazine—Photosensitivity—Losartan—type 2 diabetes mellitus	0.000469	0.00858	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Valsartan—type 2 diabetes mellitus	0.000465	0.0085	CcSEcCtD
Methotrimeprazine—Jaundice—Glyburide—type 2 diabetes mellitus	0.000464	0.00848	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Glyburide—type 2 diabetes mellitus	0.000444	0.00812	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Gliclazide—type 2 diabetes mellitus	0.000437	0.00799	CcSEcCtD
Methotrimeprazine—Weight increased—Gliclazide—type 2 diabetes mellitus	0.000436	0.00797	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Linagliptin—type 2 diabetes mellitus	0.000433	0.00792	CcSEcCtD
Methotrimeprazine—Drowsiness—Gliclazide—type 2 diabetes mellitus	0.000427	0.00781	CcSEcCtD
Methotrimeprazine—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.000425	0.0374	CbGeAlD
Methotrimeprazine—Hypersensitivity—Acarbose—type 2 diabetes mellitus	0.00042	0.00769	CcSEcCtD
Methotrimeprazine—Jaundice—Gliclazide—type 2 diabetes mellitus	0.000416	0.00761	CcSEcCtD
Methotrimeprazine—Constipation—Repaglinide—type 2 diabetes mellitus	0.000407	0.00745	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Nateglinide—type 2 diabetes mellitus	0.000405	0.00742	CcSEcCtD
Methotrimeprazine—Photosensitivity—Ramipril—type 2 diabetes mellitus	0.000402	0.00735	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Valsartan—type 2 diabetes mellitus	0.000402	0.00735	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Irbesartan—type 2 diabetes mellitus	0.0004	0.00731	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Gliclazide—type 2 diabetes mellitus	0.000399	0.00729	CcSEcCtD
Methotrimeprazine—Constipation—Rosiglitazone—type 2 diabetes mellitus	0.000385	0.00704	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Losartan—type 2 diabetes mellitus	0.000376	0.00688	CcSEcCtD
Methotrimeprazine—Tachycardia—Glimepiride—type 2 diabetes mellitus	0.000359	0.00656	CcSEcCtD
Methotrimeprazine—Drowsiness—Metformin—type 2 diabetes mellitus	0.000357	0.00653	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.000351	0.00642	CcSEcCtD
Methotrimeprazine—Somnolence—Glipizide—type 2 diabetes mellitus	0.00035	0.00641	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Irbesartan—type 2 diabetes mellitus	0.000345	0.00631	CcSEcCtD
Methotrimeprazine—Weight increased—Irbesartan—type 2 diabetes mellitus	0.000344	0.00629	CcSEcCtD
Methotrimeprazine—Constipation—Glipizide—type 2 diabetes mellitus	0.000337	0.00616	CcSEcCtD
Methotrimeprazine—HTR2A—artery—type 2 diabetes mellitus	0.000334	0.0294	CbGeAlD
Methotrimeprazine—HTR2A—nerve—type 2 diabetes mellitus	0.000331	0.0292	CbGeAlD
Methotrimeprazine—Jaundice—Irbesartan—type 2 diabetes mellitus	0.000329	0.00601	CcSEcCtD
Methotrimeprazine—Somnolence—Glimepiride—type 2 diabetes mellitus	0.000327	0.00598	CcSEcCtD
Methotrimeprazine—Somnolence—Sitagliptin—type 2 diabetes mellitus	0.000326	0.00596	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Losartan—type 2 diabetes mellitus	0.000325	0.00594	CcSEcCtD
Methotrimeprazine—Weight increased—Losartan—type 2 diabetes mellitus	0.000324	0.00592	CcSEcCtD
Methotrimeprazine—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.000324	0.00592	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Ramipril—type 2 diabetes mellitus	0.000322	0.0059	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Irbesartan—type 2 diabetes mellitus	0.000315	0.00575	CcSEcCtD
Methotrimeprazine—Constipation—Sitagliptin—type 2 diabetes mellitus	0.000314	0.00573	CcSEcCtD
Methotrimeprazine—ADRA1B—kidney—type 2 diabetes mellitus	0.000312	0.0275	CbGeAlD
Methotrimeprazine—Jaundice—Losartan—type 2 diabetes mellitus	0.000309	0.00566	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Losartan—type 2 diabetes mellitus	0.000296	0.00542	CcSEcCtD
Methotrimeprazine—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.000295	0.00539	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.00029	0.00531	CcSEcCtD
Methotrimeprazine—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000284	0.00519	CcSEcCtD
Methotrimeprazine—HTR2A—endothelium—type 2 diabetes mellitus	0.000282	0.0248	CbGeAlD
Methotrimeprazine—Photosensitivity reaction—Ramipril—type 2 diabetes mellitus	0.000279	0.00509	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000278	0.00509	CcSEcCtD
Methotrimeprazine—Weight increased—Ramipril—type 2 diabetes mellitus	0.000278	0.00508	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000271	0.00496	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.00027	0.00494	CcSEcCtD
Methotrimeprazine—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000266	0.00486	CcSEcCtD
Methotrimeprazine—Jaundice—Ramipril—type 2 diabetes mellitus	0.000265	0.00485	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Ramipril—type 2 diabetes mellitus	0.000254	0.00464	CcSEcCtD
Methotrimeprazine—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000242	0.00443	CcSEcCtD
Methotrimeprazine—CHRM2—cardiovascular system—type 2 diabetes mellitus	0.00024	0.0211	CbGeAlD
Methotrimeprazine—Constipation—Gliclazide—type 2 diabetes mellitus	0.000233	0.00426	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000223	0.00409	CcSEcCtD
Methotrimeprazine—Somnolence—Valsartan—type 2 diabetes mellitus	0.000222	0.00407	CcSEcCtD
Methotrimeprazine—CHRM1—cardiovascular system—type 2 diabetes mellitus	0.000218	0.0192	CbGeAlD
Methotrimeprazine—Constipation—Valsartan—type 2 diabetes mellitus	0.000214	0.00391	CcSEcCtD
Methotrimeprazine—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.00021	0.00384	CcSEcCtD
Methotrimeprazine—DRD2—retina—type 2 diabetes mellitus	0.000208	0.0183	CbGeAlD
Methotrimeprazine—Somnolence—Metformin—type 2 diabetes mellitus	0.000203	0.0037	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000201	0.00367	CcSEcCtD
Methotrimeprazine—Tachycardia—Losartan—type 2 diabetes mellitus	0.000198	0.00361	CcSEcCtD
Methotrimeprazine—Constipation—Metformin—type 2 diabetes mellitus	0.000195	0.00356	CcSEcCtD
Methotrimeprazine—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000191	0.0035	CcSEcCtD
Methotrimeprazine—CHRM3—kidney—type 2 diabetes mellitus	0.000191	0.0168	CbGeAlD
Methotrimeprazine—ADRA2C—nephron tubule—type 2 diabetes mellitus	0.00019	0.0168	CbGeAlD
Methotrimeprazine—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000189	0.0166	CbGeAlD
Methotrimeprazine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000184	0.00337	CcSEcCtD
Methotrimeprazine—Constipation—Irbesartan—type 2 diabetes mellitus	0.000184	0.00336	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000182	0.00333	CcSEcCtD
Methotrimeprazine—Somnolence—Losartan—type 2 diabetes mellitus	0.00018	0.00329	CcSEcCtD
Methotrimeprazine—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000179	0.0158	CbGeAlD
Methotrimeprazine—Constipation—Losartan—type 2 diabetes mellitus	0.000173	0.00316	CcSEcCtD
Methotrimeprazine—CHRM3—adipose tissue—type 2 diabetes mellitus	0.000172	0.0152	CbGeAlD
Methotrimeprazine—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000169	0.0031	CcSEcCtD
Methotrimeprazine—ADRA2C—kidney—type 2 diabetes mellitus	0.000167	0.0147	CbGeAlD
Methotrimeprazine—ADRA2C—pancreas—type 2 diabetes mellitus	0.000166	0.0146	CbGeAlD
Methotrimeprazine—ADRA2C—cortex of kidney—type 2 diabetes mellitus	0.000163	0.0143	CbGeAlD
Methotrimeprazine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000158	0.0029	CcSEcCtD
Methotrimeprazine—ADRA1A—adipose tissue—type 2 diabetes mellitus	0.000158	0.0139	CbGeAlD
Methotrimeprazine—Somnolence—Ramipril—type 2 diabetes mellitus	0.000154	0.00282	CcSEcCtD
Methotrimeprazine—ADRA2C—adipose tissue—type 2 diabetes mellitus	0.000151	0.0133	CbGeAlD
Methotrimeprazine—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000149	0.00273	CcSEcCtD
Methotrimeprazine—CYP2E1—nephron tubule—type 2 diabetes mellitus	0.000149	0.0131	CbGeAlD
Methotrimeprazine—Constipation—Ramipril—type 2 diabetes mellitus	0.000148	0.00271	CcSEcCtD
Methotrimeprazine—Fluphenazine—CALM1—type 2 diabetes mellitus	0.00014	0.0507	CrCbGaD
Methotrimeprazine—HTR2A—retina—type 2 diabetes mellitus	0.000137	0.0121	CbGeAlD
Methotrimeprazine—CYP2E1—cardiovascular system—type 2 diabetes mellitus	0.000133	0.0118	CbGeAlD
Methotrimeprazine—ADRA2A—pancreas—type 2 diabetes mellitus	0.000133	0.0117	CbGeAlD
Methotrimeprazine—CYP2E1—kidney—type 2 diabetes mellitus	0.000131	0.0115	CbGeAlD
Methotrimeprazine—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.00013	0.0114	CbGeAlD
Methotrimeprazine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000128	0.00234	CcSEcCtD
Methotrimeprazine—CYP2E1—cortex of kidney—type 2 diabetes mellitus	0.000127	0.0112	CbGeAlD
Methotrimeprazine—HRH1—adipose tissue—type 2 diabetes mellitus	0.000122	0.0108	CbGeAlD
Methotrimeprazine—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.00012	0.0106	CbGeAlD
Methotrimeprazine—Propericiazine—ADRA2A—type 2 diabetes mellitus	0.000118	0.043	CrCbGaD
Methotrimeprazine—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.000116	0.0102	CbGeAlD
Methotrimeprazine—HTR2A—kidney—type 2 diabetes mellitus	0.000113	0.00999	CbGeAlD
Methotrimeprazine—Promethazine—CALM1—type 2 diabetes mellitus	0.000113	0.0411	CrCbGaD
Methotrimeprazine—Trifluoperazine—CALM1—type 2 diabetes mellitus	0.000112	0.0406	CrCbGaD
Methotrimeprazine—ADRA1A—liver—type 2 diabetes mellitus	0.000111	0.00977	CbGeAlD
Methotrimeprazine—Perphenazine—CALM1—type 2 diabetes mellitus	0.00011	0.0401	CrCbGaD
Methotrimeprazine—Cyamemazine—HTR2C—type 2 diabetes mellitus	0.000109	0.0396	CrCbGaD
Methotrimeprazine—ADRA2C—liver—type 2 diabetes mellitus	0.000106	0.00931	CbGeAlD
Methotrimeprazine—CYP2D6—kidney—type 2 diabetes mellitus	0.000103	0.00911	CbGeAlD
Methotrimeprazine—CYP1A2—liver—type 2 diabetes mellitus	9.17e-05	0.00808	CbGeAlD
Methotrimeprazine—Chlorpromazine—CALM1—type 2 diabetes mellitus	8.77e-05	0.0318	CrCbGaD
Methotrimeprazine—CYP2E1—liver—type 2 diabetes mellitus	8.25e-05	0.00727	CbGeAlD
Methotrimeprazine—HTR2A—liver—type 2 diabetes mellitus	7.17e-05	0.00632	CbGeAlD
Methotrimeprazine—Mesoridazine—HTR2C—type 2 diabetes mellitus	6.65e-05	0.0241	CrCbGaD
Methotrimeprazine—CYP2D6—liver—type 2 diabetes mellitus	6.53e-05	0.00576	CbGeAlD
Methotrimeprazine—Prochlorperazine—HTR2C—type 2 diabetes mellitus	6.44e-05	0.0234	CrCbGaD
Methotrimeprazine—Fluphenazine—ADRA2A—type 2 diabetes mellitus	6.32e-05	0.023	CrCbGaD
Methotrimeprazine—Fluphenazine—HTR2C—type 2 diabetes mellitus	5.82e-05	0.0211	CrCbGaD
Methotrimeprazine—Clomipramine—ADRA2A—type 2 diabetes mellitus	5.78e-05	0.021	CrCbGaD
Methotrimeprazine—Propiomazine—HTR2C—type 2 diabetes mellitus	5.6e-05	0.0203	CrCbGaD
Methotrimeprazine—Alimemazine—CYP3A4—type 2 diabetes mellitus	5.5e-05	0.02	CrCbGaD
Methotrimeprazine—Thioridazine—ADRA2A—type 2 diabetes mellitus	5.45e-05	0.0198	CrCbGaD
Methotrimeprazine—Clomipramine—HTR2C—type 2 diabetes mellitus	5.33e-05	0.0193	CrCbGaD
Methotrimeprazine—Trimipramine—ADRA2A—type 2 diabetes mellitus	5.32e-05	0.0193	CrCbGaD
Methotrimeprazine—Chlorprothixene—HTR2C—type 2 diabetes mellitus	5.3e-05	0.0192	CrCbGaD
Methotrimeprazine—Pipotiazine—CYP1A2—type 2 diabetes mellitus	5.08e-05	0.0185	CrCbGaD
Methotrimeprazine—Thioridazine—HTR2C—type 2 diabetes mellitus	5.02e-05	0.0182	CrCbGaD
Methotrimeprazine—Perphenazine—ADRA2A—type 2 diabetes mellitus	5e-05	0.0182	CrCbGaD
Methotrimeprazine—Trimipramine—HTR2C—type 2 diabetes mellitus	4.9e-05	0.0178	CrCbGaD
Methotrimeprazine—Mequitazine—CYP3A4—type 2 diabetes mellitus	4.73e-05	0.0172	CrCbGaD
Methotrimeprazine—Trifluoperazine—HTR2C—type 2 diabetes mellitus	4.65e-05	0.0169	CrCbGaD
Methotrimeprazine—Fluphenazine—CYP2E1—type 2 diabetes mellitus	4.62e-05	0.0168	CrCbGaD
Methotrimeprazine—Perphenazine—HTR2C—type 2 diabetes mellitus	4.6e-05	0.0167	CrCbGaD
Methotrimeprazine—Promazine—ADRA2A—type 2 diabetes mellitus	4.51e-05	0.0164	CrCbGaD
Methotrimeprazine—Fluphenazine—CYP1A2—type 2 diabetes mellitus	4.39e-05	0.0159	CrCbGaD
Methotrimeprazine—Diltiazem—CYP3A4—type 2 diabetes mellitus	4.24e-05	0.0154	CrCbGaD
Methotrimeprazine—Promazine—HTR2C—type 2 diabetes mellitus	4.15e-05	0.0151	CrCbGaD
Methotrimeprazine—Clomipramine—CYP1A2—type 2 diabetes mellitus	4.02e-05	0.0146	CrCbGaD
Methotrimeprazine—Thioridazine—CYP2E1—type 2 diabetes mellitus	3.98e-05	0.0144	CrCbGaD
Methotrimeprazine—Chlorpromazine—ADRA2A—type 2 diabetes mellitus	3.97e-05	0.0144	CrCbGaD
Methotrimeprazine—Thioridazine—CYP1A2—type 2 diabetes mellitus	3.79e-05	0.0137	CrCbGaD
Methotrimeprazine—Chlorpromazine—HTR2C—type 2 diabetes mellitus	3.65e-05	0.0133	CrCbGaD
Methotrimeprazine—Imipramine—HTR2C—type 2 diabetes mellitus	3.63e-05	0.0132	CrCbGaD
Methotrimeprazine—Trifluoperazine—CYP1A2—type 2 diabetes mellitus	3.51e-05	0.0127	CrCbGaD
Methotrimeprazine—Perphenazine—CYP1A2—type 2 diabetes mellitus	3.47e-05	0.0126	CrCbGaD
Methotrimeprazine—Pipotiazine—CYP3A4—type 2 diabetes mellitus	3.37e-05	0.0122	CrCbGaD
Methotrimeprazine—Prochlorperazine—CYP3A4—type 2 diabetes mellitus	3.22e-05	0.0117	CrCbGaD
Methotrimeprazine—Promazine—CYP1A2—type 2 diabetes mellitus	3.13e-05	0.0114	CrCbGaD
Methotrimeprazine—Acepromazine—ALB—type 2 diabetes mellitus	3.05e-05	0.0111	CrCbGaD
Methotrimeprazine—Thioproperazine—ALB—type 2 diabetes mellitus	2.98e-05	0.0108	CrCbGaD
Methotrimeprazine—Pipotiazine—ALB—type 2 diabetes mellitus	2.94e-05	0.0107	CrCbGaD
Methotrimeprazine—Chlorpromazine—CYP2E1—type 2 diabetes mellitus	2.9e-05	0.0105	CrCbGaD
Methotrimeprazine—Imipramine—CYP2E1—type 2 diabetes mellitus	2.88e-05	0.0105	CrCbGaD
Methotrimeprazine—Chlorpromazine—CYP1A2—type 2 diabetes mellitus	2.76e-05	0.01	CrCbGaD
Methotrimeprazine—Imipramine—CYP1A2—type 2 diabetes mellitus	2.74e-05	0.00995	CrCbGaD
Methotrimeprazine—Clomipramine—CYP3A4—type 2 diabetes mellitus	2.66e-05	0.00966	CrCbGaD
Methotrimeprazine—Trimipramine—CYP3A4—type 2 diabetes mellitus	2.45e-05	0.00888	CrCbGaD
Methotrimeprazine—Clomipramine—ALB—type 2 diabetes mellitus	2.32e-05	0.00842	CrCbGaD
Methotrimeprazine—Perphenazine—CYP3A4—type 2 diabetes mellitus	2.3e-05	0.00835	CrCbGaD
Methotrimeprazine—Promazine—CYP3A4—type 2 diabetes mellitus	2.07e-05	0.00753	CrCbGaD
Methotrimeprazine—Chlorpromazine—CYP3A4—type 2 diabetes mellitus	1.82e-05	0.00662	CrCbGaD
Methotrimeprazine—Imipramine—CYP3A4—type 2 diabetes mellitus	1.82e-05	0.00659	CrCbGaD
Methotrimeprazine—Chlorpromazine—ALB—type 2 diabetes mellitus	1.59e-05	0.00578	CrCbGaD
Methotrimeprazine—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	1.3e-06	1.6e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.3e-06	1.6e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.3e-06	1.6e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.3e-06	1.59e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.29e-06	1.59e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.29e-06	1.58e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.29e-06	1.58e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.28e-06	1.58e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.28e-06	1.58e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.28e-06	1.58e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.28e-06	1.57e-05	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—IL6—type 2 diabetes mellitus	1.27e-06	1.57e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.27e-06	1.56e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.27e-06	1.56e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	1.26e-06	1.56e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.26e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.26e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—NOS3—type 2 diabetes mellitus	1.26e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.26e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.26e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.26e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.26e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.26e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.26e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	1.26e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.26e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.26e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.25e-06	1.54e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.25e-06	1.54e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.25e-06	1.54e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.25e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—SRC—type 2 diabetes mellitus	1.24e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—SRC—type 2 diabetes mellitus	1.24e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.24e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.24e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.24e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.24e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.23e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.23e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	1.23e-06	1.51e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.23e-06	1.51e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.22e-06	1.51e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.22e-06	1.51e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.22e-06	1.5e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.21e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.21e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.21e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.21e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.21e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	1.21e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.21e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.2e-06	1.48e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.2e-06	1.48e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.2e-06	1.48e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.2e-06	1.48e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.19e-06	1.47e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.19e-06	1.47e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.19e-06	1.47e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.19e-06	1.46e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.19e-06	1.46e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	1.18e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.18e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.18e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.18e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.18e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	1.18e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	1.18e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.18e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.18e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.17e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.17e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.17e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.16e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.16e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.15e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PTGS2—type 2 diabetes mellitus	1.15e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.15e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.15e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	1.15e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.13e-06	1.4e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	1.13e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.13e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.12e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.12e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.12e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.12e-06	1.37e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.11e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.11e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.1e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.1e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.1e-06	1.35e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.1e-06	1.35e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.09e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.09e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	1.09e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.09e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.09e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.08e-06	1.33e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.08e-06	1.33e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.08e-06	1.33e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.08e-06	1.33e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.08e-06	1.33e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.08e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	1.08e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.07e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.07e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.07e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	1.07e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.07e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.07e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.06e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.06e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.06e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.06e-06	1.3e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.06e-06	1.3e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.06e-06	1.3e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.05e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.05e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.05e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	1.05e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.05e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.04e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.04e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	1.03e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.03e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.03e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.02e-06	1.26e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.02e-06	1.25e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.02e-06	1.25e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	1.02e-06	1.25e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.01e-06	1.25e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	1.01e-06	1.25e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.01e-06	1.24e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.01e-06	1.24e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	1e-06	1.24e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1e-06	1.23e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1e-06	1.23e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1e-06	1.23e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	1e-06	1.23e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1e-06	1.23e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.99e-07	1.23e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.97e-07	1.23e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.95e-07	1.22e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.94e-07	1.22e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.92e-07	1.22e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.84e-07	1.21e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.84e-07	1.21e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.83e-07	1.21e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.82e-07	1.21e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.81e-07	1.21e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.8e-07	1.21e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.77e-07	1.2e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.75e-07	1.2e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.74e-07	1.2e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.69e-07	1.19e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.65e-07	1.19e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.62e-07	1.18e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.62e-07	1.18e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	9.49e-07	1.17e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.43e-07	1.16e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—IL6—type 2 diabetes mellitus	9.41e-07	1.16e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	9.36e-07	1.15e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.35e-07	1.15e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	9.34e-07	1.15e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—SRC—type 2 diabetes mellitus	9.32e-07	1.15e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	9.29e-07	1.14e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—IL6—type 2 diabetes mellitus	9.28e-07	1.14e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	9.26e-07	1.14e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.25e-07	1.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.22e-07	1.13e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.2e-07	1.13e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	9.17e-07	1.13e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.17e-07	1.13e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	9.15e-07	1.13e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.12e-07	1.12e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.1e-07	1.12e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.08e-07	1.12e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.05e-07	1.11e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.02e-07	1.11e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.02e-07	1.11e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	8.95e-07	1.1e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	8.95e-07	1.1e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.94e-07	1.1e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.93e-07	1.1e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.91e-07	1.1e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—IL6—type 2 diabetes mellitus	8.89e-07	1.09e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	8.82e-07	1.08e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.68e-07	1.07e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	8.65e-07	1.06e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.56e-07	1.05e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	8.5e-07	1.05e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.49e-07	1.04e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	8.47e-07	1.04e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—IL6—type 2 diabetes mellitus	8.36e-07	1.03e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—IL6—type 2 diabetes mellitus	8.36e-07	1.03e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.35e-07	1.03e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.33e-07	1.02e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.32e-07	1.02e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.3e-07	1.02e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.28e-07	1.02e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.28e-07	1.02e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.2e-07	1.01e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.2e-07	1.01e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	8.19e-07	1.01e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.19e-07	1.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.18e-07	1.01e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.17e-07	1e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.14e-07	1e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.12e-07	9.99e-06	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.04e-07	9.89e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.02e-07	9.86e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	7.93e-07	9.75e-06	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.81e-07	9.61e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	7.78e-07	9.56e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.71e-07	9.48e-06	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.71e-07	9.48e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.6e-07	9.34e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	7.58e-07	9.33e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	7.58e-07	9.33e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	7.54e-07	9.28e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.45e-07	9.16e-06	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	7.25e-07	8.91e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	7.05e-07	8.67e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.96e-07	8.56e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	6.94e-07	8.53e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL6—type 2 diabetes mellitus	6.94e-07	8.53e-06	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	6.88e-07	8.47e-06	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.68e-07	8.22e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.5e-07	8e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.4e-07	7.87e-06	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	6.39e-07	7.87e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	6.32e-07	7.77e-06	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	6.29e-07	7.74e-06	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL6—type 2 diabetes mellitus	6.28e-07	7.72e-06	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	6.26e-07	7.7e-06	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	6.24e-07	7.67e-06	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	6.18e-07	7.6e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	6.16e-07	7.58e-06	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.9e-07	7.26e-06	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.8e-07	7.14e-06	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—AKT1—type 2 diabetes mellitus	5.8e-07	7.13e-06	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.79e-07	7.12e-06	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.77e-07	7.1e-06	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.75e-07	7.08e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	5.72e-07	7.04e-06	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.7e-07	7.01e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.68e-07	6.99e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.28e-07	6.5e-06	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	4.12e-07	5.06e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	3.49e-07	4.29e-06	CbGpPWpGaD
